RxDoctor Payments Data

Delorise Brown, MD

Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1023129079

Payments from drug & device makers

$838in general payments, 2019–2025

Across 49 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$331
  • Pfizer$177
  • Astellas Pharma US Inc$69
  • AstraZeneca$68
  • Mannkind Corporation$55
  • Merck$32
  • plus $106 from 6 others

What the payments were for

  • Food & beverage$838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$838 in reported general payments places this provider in the 40th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$16,084
Medicare patients
36
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$103,779
TrulicityDulaglutide58$85,485
EliquisApixaban32$38,444
LinzessLinaclotide29$37,370
JardianceEmpagliflozin20$30,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$23,965
MyrbetriqMirabegron26$19,194
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$7,654
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,406
TradjentaLinagliptin14$6,817
Lidocaine19$6,040
Gabapentin155$4,891
Humalog Kwikpen U-100Insulin Lispro24$4,885
Breo ElliptaFluticasone/Vilanterol11$4,456
Colchicine36$3,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$331$103,77973 claims
AbbVieLinzess, Synthroid$16$39,10045 claims
PfizerEliquis$177$38,44432 claims
Astellas Pharma US IncMyrbetriq$69$19,19426 claims
Scilex Pharmaceuticals Inc.Colchicine$18$3,16236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →